FLOVENT
Total Payments
$461,909
Transactions
27
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $223,545 | 9 | 0 |
| 2022 | $83,634 | 6 | 0 |
| 2020 | $49,629 | 3 | 0 |
| 2019 | $90,407 | 4 | 0 |
| 2018 | $14,675 | 4 | 2 |
| 2017 | $20.00 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $461,764 | 23 | 100.0% |
| Education | $124.50 | 3 | 0.0% |
| Food and Beverage | $20.00 | 1 | 0.0% |
Payments by Type
Research
$461,764
23 transactions
General
$144.50
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 208071 | GlaxoSmithKline, LLC. | $232,152 | 0 |
| 207661 | GlaxoSmithKline, LLC. | $71,589 | 0 |
| 207661-ORBEX | GlaxoSmithKline, LLC. | $14,550 | 0 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $461,909
Product Information
- Type Drug
- Total Payments $461,909
- Total Doctors 3
- Transactions 27
About FLOVENT
FLOVENT is a drug associated with $461,909 in payments to 3 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2023. In 2023, $223,545 was paid across 9 transactions to 0 doctors.
The most common payment nature for FLOVENT is "Unspecified" ($461,764, 100.0% of total).
FLOVENT is associated with 3 research studies, including "208071" ($232,152).